Feline Blastomycosis

Feline blastomycosis is a rare systemic fungal infection of cats caused by the thermally dimorphic fungus Blastomyces dermatitidis. Unlike in dogs, where blastomycosis is recognized as a significant clinical problem, the disease is notably uncommon in cats, making comprehensive epidemiological and clinical data scarce [1]. Infection typically follows inhalation of fungal conidia from contaminated soil or decaying organic matter in endemic geographic regions, after which the organism can disseminate hematogenously to multiple organ systems [2]. Due to its rarity in feline patients, diagnosis is often delayed, and the disease may be easily overlooked in the absence of a high index of clinical suspicion [1].

Causative Agent

Feline blastomycosis is caused by Blastomyces dermatitidis, a thermally dimorphic fungus that exists as a mycelial (mold) form in the environment and converts to a pathogenic yeast form at host body temperature (37–39°C) [1][2]. A closely related species, Blastomyces gilchristii, has been identified in some geographic regions and may also cause disease, though molecular epidemiological work has primarily focused on B. dermatitidis [6].

Environmental Reservoir and Geographic Distribution

The organism inhabits moist, acidic soils rich in organic matter, particularly near waterways, lakes, and rivers. It is endemic to the Mississippi and Ohio River valleys, the Great Lakes region, and parts of Canada, including Ontario and Manitoba [1][3][6]. Veterinary surveys in Wisconsin have documented significant disease burden in this endemic region [3][6]. Sporadic cases have been reported outside endemic zones [4].

Pathogenesis

The primary route of infection is inhalation of small-diameter conidia aerosolized from soil disturbance [2]. Once deposited in the terminal bronchioles and alveoli, conidia convert to the yeast phase and trigger a pyogranulomatous inflammatory response involving macrophages, neutrophils, and giant cells [1][2]. Cell-mediated immunity is the primary host defense; immunocompetent animals may contain infection to the lungs, while impaired or overwhelmed immunity permits hematogenous and lymphatic dissemination to the skin, eyes, bones, central nervous system, and other tissues [1][4]. In cats, the nasal cavity appears to be a site of particular predilection, with direct extension causing osteolysis of nasal bones and facial soft tissue involvement [5]. The organism is not transmitted between individual animals or from animals to humans via direct contact; infection requires exposure to the environmental reservoir [1][4].

Risk Factors

Outdoor access in endemic geographic regions is the most important risk factor [1][4]. Male animals and those with increased environmental exposure (e.g., hunting dogs) have higher incidence in canine epidemiology; analogous feline risk factors are poorly defined due to the disease's rarity in cats [1][3]. Since fungal spores are airborne, even indoor-only cats in endemic regions remain theoretically susceptible [4].

Clinical Suspicion

Diagnosis begins with recognizing compatible clinical signs (respiratory distress, skin lesions, ocular disease, epistaxis, or facial swelling) in a cat with a history of residence in or travel to an endemic area [1][5]. Because the disease is rare in cats, clinicians must maintain a high index of suspicion to avoid diagnostic delays [1].

Cytology and Histopathology

Definitive diagnosis most commonly relies on cytological or histopathological identification of the characteristic broad-based budding yeast form of B. dermatitidis (8–20 μm diameter) within pyogranulomatous lesions [1][4][5]. Samples may be obtained via fine-needle aspirates of lymph nodes, skin lesions, or masses; bronchoalveolar lavage or transtracheal wash for pulmonary cases; and biopsy of nasal or other affected tissues [1][5]. In the nasal blastomycosis case reported by Bolton et al. (2024), histopathology of nasal mass biopsies and cytology of facial swelling fluid both revealed pyogranulomatous inflammation with B. dermatitidis organisms [5]. The limitation is that multiple cytologic samples may be unrewarding, delaying diagnosis [1].

Fungal Culture

Isolation of B. dermatitidis from clinical specimens confirms the diagnosis but is technically challenging, slow (weeks to months), and poses biohazard risks to laboratory personnel due to the infectious mycelial form [1][2]. Culture is not recommended as a first-line test in clinical practice but may be pursued in referral or research settings [1].

Serology

Agar gel immunodiffusion (AGID) and enzyme immunoassay (EIA) for Blastomyces antibodies are available; however, sensitivity and specificity in cats are not well-established, and serologic testing in feline patients is less validated than in dogs or humans [1][4]. Seronegative results do not exclude infection.

Urine Antigen Testing

A urine antigen detection assay (MiraVista Diagnostics) is available and has shown utility in human and canine blastomycosis; however, cross-reactivity with other fungi (e.g., Histoplasma) can occur, and performance data in cats are limited [1][4]. It may serve as a useful adjunct when cytology is inconclusive.

Imaging

• ·Thoracic radiography: May reveal a mixed interstitial-alveolar or nodular pulmonary pattern, hilar lymphadenopathy, or miliary densities consistent with fungal pneumonia [2][4]
• ·Computed tomography (CT): CT of the head, thorax, or affected regions provides superior anatomical detail; in one feline case, contrast-enhanced head CT identified a nasal cavity mass and multifocal nasal bone osteolysis consistent with invasive fungal disease [5]
• ·Skull/skeletal radiography or CT: Osteolytic lesions may be apparent in cases with bone involvement [1]

Clinically Relevant Laboratory Findings

Routine hematological and biochemical changes in feline blastomycosis are not well characterized due to the small number of reported cases, but findings analogous to those in dogs and consistent with systemic fungal infection may include:

• ·CBC: Leukocytosis (elevated WBC) with a neutrophilia, often with a left shift, reflecting pyogranulomatous inflammation; anemia (low HCT) of chronic disease or inflammation; thrombocytopenia (low PLT) in severe or disseminated cases [2][4]
• ·Serum chemistry: Hypoalbuminemia (low ALB) and hyperglobulinemia (high GLOB) reflecting chronic inflammation and immune activation; elevated liver enzymes (elevated ALT) if hepatic involvement is present; elevated BUN and CREA if renal dissemination occurs [2][4]
• ·Total bilirubin (TBIL): May be mildly elevated with hepatic involvement, though this is uncommonly reported [4]

Antifungal Therapy

Azole antifungals, particularly itraconazole, are the cornerstone of treatment for feline blastomycosis, as they are for the disease in dogs and humans [1][2][4]. Itraconazole is preferred due to its favorable safety profile relative to amphotericin B and good tissue penetration, including into the lung, skin, and bones.

• ·Itraconazole: Typically administered at 5–10 mg/kg orally once or twice daily; in the documented feline nasal blastomycosis case, the cat received itraconazole for 8 months with complete resolution of clinical signs [5]. Treatment duration is often prolonged (minimum 6–12 months or longer), and therapy should be continued until clinical signs resolve and diagnostic markers indicate clearance [1][5]
• ·Fluconazole: An alternative azole with better CNS penetration, which may be preferred in cases with neurological or ocular dissemination; however, it is considered less potent against Blastomyces than itraconazole [1][4]
• ·Voriconazole: A second-generation triazole that may be considered in refractory cases; cats are notably sensitive to voriconazole toxicity (neurological side effects and visual disturbances have been reported), and its use in cats requires great caution and careful monitoring [4]
• ·Amphotericin B (AMB): Reserved for severely ill patients or those who fail azole therapy; administered intravenously or as a lipid-complex formulation to reduce nephrotoxicity; renal function (BUN, CREA) must be monitored closely during AMB therapy [1][2]. The lipid-based formulations (e.g., liposomal AMB) are associated with fewer adverse effects [4]
• ·Posaconazole and isavuconazole: Newer azoles with in vitro activity against Blastomyces; clinical data in cats are insufficient to make firm recommendations, but they may represent options in refractory cases [4]

Monitoring During Treatment

• ·Periodic thoracic radiographs and/or CT to assess pulmonary and tissue response [1]
• ·Repeat cytology or antigen titers (where applicable) to document clearance [1]
• ·Liver enzyme monitoring (ALT) during prolonged itraconazole therapy due to potential hepatotoxicity [4]
• ·Renal function tests (BUN, CREA) if amphotericin B is used [1][2]

Supportive Care

• ·Nutritional support, appetite stimulants, and assisted feeding for anorexic or cachectic patients [2]
• ·Ocular lubricants and anti-inflammatory topical medications for cats with uveitis or ocular involvement, in consultation with an ophthalmologist [4]
• ·Surgical debulking or biopsy of accessible masses may be performed for diagnostic purposes and potentially to reduce fungal burden, as was done in the nasal blastomycosis case [5]
• ·Oxygen supplementation for cats with significant respiratory compromise [2]

Feline blastomycosis is considered a serious, potentially life-threatening disease, and the prognosis depends heavily on the extent of dissemination at the time of diagnosis, the organ systems involved, and the promptness of antifungal therapy [1][4].

Published Outcome Data

Explicit survival statistics for feline blastomycosis are not reported in the available veterinary literature, primarily because the disease is rare enough in cats that large case series do not exist [1]. However, the following relevant information can be extrapolated:

• ·In the published feline nasal blastomycosis case (Bolton et al., 2024), the cat achieved complete resolution of clinical signs following 8 months of itraconazole therapy, suggesting that favorable outcomes are possible with appropriate treatment of localized or nasal disease [5]
• ·In dogs, with which more epidemiological data exist, prognosis varies considerably by disease severity; Wisconsin veterinary practice surveys indicate that canine blastomycosis carries significant morbidity and some mortality, particularly in severe pulmonary or disseminated cases [3]
• ·Werner and Norton (2011) note that the most significant clinical dilemma in blastomycosis is the inability to make a timely diagnosis when cytologic samples are unrewarding, which implies that delayed diagnosis worsens outcomes [1]
• ·Disseminated disease involving the CNS, eyes, or multiple organ systems is generally associated with a guarded to poor prognosis in both cats and dogs [1][4]
• ·Mycotic pneumonias as a class carry variable prognosis depending on fungal burden and host immune status; respiratory compromise is a significant negative prognostic factor [2]

Prognostic Factors

• ·Favorable: Localized disease (e.g., nasal cavity alone), early diagnosis, good owner compliance with prolonged antifungal treatment, intact immune function
• ·Unfavorable: CNS involvement, severe pulmonary disease, bilateral ocular disease causing blindness, profound debilitation or immunosuppression, delayed diagnosis

Data Limitation Note: Peer-reviewed survival statistics specifically for feline blastomycosis are not available in the current literature due to the rarity of the condition in this species. The mortality rate metadata below reflects an expert estimate based on disease severity and analogy with canine disease, not a direct feline case-fatality figure.

Environmental Avoidance

There is no licensed vaccine for blastomycosis in any species [1][4]. Prevention is therefore focused on minimizing exposure to environmental risk factors:

• ·Restricting outdoor access for cats in known endemic areas, particularly near bodies of water, riverbanks, and wooded areas with moist, organic-rich soil, reduces the risk of conidia inhalation [1][4]
• ·Indoor-only housing is a practical preventive strategy for cats in hyperendemic regions, though it cannot fully eliminate risk since spores may be carried indoors on clothing, footwear, or through ventilation systems [4]
• ·Avoiding activities that disturb soil (e.g., excavation, digging, or exposure to construction sites) in endemic areas limits aerosolization of conidia [1]

No Chemoprophylaxis

Routine antifungal prophylaxis is not recommended or practiced in cats, even in endemic regions, due to lack of evidence supporting its efficacy, the risk of antifungal drug toxicity, the potential for development of resistance, and the rarity of disease in cats [4].

Owner Education

Veterinarians practicing in endemic regions should educate cat owners about the risk of blastomycosis, the importance of reporting compatible clinical signs promptly, and the value of early diagnostic workup [1][3]. Awareness of the endemic geographic range is critical, as cats traveling to or relocated from endemic areas may present with blastomycosis in non-endemic regions where clinicians may be less familiar with the disease [4][6].

No Animal-to-Human or Animal-to-Animal Transmission

Because Blastomyces dermatitidis is not transmitted between individual animals or from cats to humans via direct contact, isolation of infected cats is not required for prevention of spread; however, standard infection control practices should be followed when handling draining lesions [1][4].